Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04302181 · ClinicalTrials.gov registry record · Early Phase 1
Augmenting Massed Prolonged Exposure With a Stellate Ganglion Block to Treat PTSD
A Early Phase 1 study, sponsored by The University of Texas Health Science Center at San Antonio.
- Completed
- Registry status
- Early Phase 1
- Development phase
- 12
- Enrollment target
NCT04302181 is a Early Phase 1 study that has completed, run by The University of Texas Health Science Center at San Antonio. The registered enrollment target is 12 participants.
The verdict
NCT04302181, a Early Phase 1 study, has completed, sponsored by The University of Texas Health Science Center at San Antonio.
- COMPLETED
- Registry status
- Early Phase 1
- Development phase
- 12 participants
- Enrollment target
Study Summary
This is a small, open-label treatment study that tests the potential safety and treatment effectiveness of a stellate ganglion block combined with Massed Prolonged Exposure (PE). Each of the 12 participants will receive ten 90-minute sessions of Massed Prolonged Exposure and an injection of a stellate ganglion block between the first and second PE sessions.
Interventions
- DRUG Ropivacaine injection
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 12 participants |
| Start Date | 2020-10-05 |
| Est. Completion | 2021-12-03 |
| Phase | Early Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04302181
The ClinicalTrials.gov registry entry for NCT04302181 describes a study currently listed as completed, categorized as Early Phase 1. The registered enrollment target is 12 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is The University of Texas Health Science Center at San Antonio, which has 378 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Ropivacaine injection is the first listed.
NCT04302181 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04302181 about?
NCT04302181 is a clinical study titled "Augmenting Massed Prolonged Exposure With a Stellate Ganglion Block to Treat PTSD". This is a small, open-label treatment study that tests the potential safety and treatment effectiveness of a stellate ganglion block combined with Massed Prolonged Exposure (PE). Each of the 12 participants will receive ten 90-minute sessions of Massed Prolonged Exposure and an injection of a stella...
What is the current status of trial NCT04302181?
This trial is currently completed. It is a Early Phase 1 study. The enrollment target is 12 participants. The study started on 2020-10-05. Estimated completion is 2021-12-03.
What interventions are being tested in trial NCT04302181?
The interventions under investigation include: Ropivacaine injection (DRUG).
Who is sponsoring clinical trial NCT04302181?
This trial is sponsored by The University of Texas Health Science Center at San Antonio, which has 378 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.